Myeloma UK is attending the 2017 British Society of Haematology’s (BSH) Annual Scientific Meeting, which this year takes place in Brighton.
Monica Morris is our Healthcare Professional Manager and is part of the Myeloma UK team attending the conference, “The BSH Annual Meeting attracts leading haematologists from across the UK to discuss the latest developments, not just in myeloma, but across a number of other haematological areas, and is a great opportunity for haematology doctors and nurses to learn about the latest developments in myeloma treatment and care.”
“For Myeloma UK, it also provides a chance to discuss the latest developments in research and myeloma care, as well as allowing us to explain our Myeloma Academy programme to healthcare professionals.”
The Myeloma Academy provides healthcare professionals with a range of innovative educational resources to develop their knowledge of myeloma.
Monica continues, “The Myeloma Academy is a great resource to healthcare professionals keen to take a closer look at myeloma treatment and care. We’ll also be telling delegates about our Myeloma Academy Roadshows, taking place this year in Bath, Newcastle and Leicester. These events provide healthcare professionals with an opportunity to take part in provocative debates with leading experts and discuss treatment and management issues in myeloma.”
Attending events like BSH is just one of the ways Myeloma UK supports healthcare professionals as part of our work to influence positive changes in practice that ultimately benefit patients. Find out more about our work to support healthcare professionals.
Myeloma UK is also contributing to conference’s programme, with a poster presentation by our Health Services Research Manager Dr Jayne Galinsky on the outcomes of older patients who are not eligible for high dose therapy and stem cell transplantation (HDT-SCT).
Dr Dunnya De-Silva carried out the study and explains, “This review looked into what could help older newly diagnosed patients achieve long periods of time without their myeloma returning (progression-free survival), such as an earlier diagnosis or different forms of treatment.”
Jayne adds, “It’s great to share these results with BSH delegates and we will also be publishing our findings very soon.”